Headache and Migraine

The primary pharmaceutical options suggested by national guidelines were considered effective by only 13.8% and 14.9% of the patients with persistent idiopathic facial pain.

Here's what is coming soon to NeurologyLive.

Roderick Spears, MD, FAHS, FAAN, professor of neurology, University of Pennsylvania, discussed the need to raise awareness of migraine and how the community can build upon the progress made.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 15, 2021.

The headache specialist at Jefferson Headache Center discussed the array of issues patients with migraine face and why her personal experience may resonate with patients. [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive.

The division chief of vascular neurology at the University of Utah discussed the individual role that clinicians and neurologists can play to increase interest in the field of neurology. [WATCH TIME: 2 minutes]

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 8, 2021.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

During the double-blind treatment phase, rates of hypertension AEs were low for the placebo and erenumab 70- and 140-mg treatment groups, as well as during open-label erenumab treatment.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 1, 2021.

Children and adults with migraine displayed significantly less REM sleep as a percentage of total sleep time than healthy individuals.

Expert clinicians offer their perspectives on the ongoing shortage of neurologists, transgender and gender-diverse individuals with migraine, artificial intelligence and neuroimaging, Student Sleep Health Week 2021, and the importance of rehabilitation therapy in multiple sclerosis.

The gepant, marketed as Qulipta, is the first oral calcitonin gene-related peptide receptor antagonist approved for episodic migraine.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 24, 2021.

Deena Kuruvilla, MD, director, Westport Headache Institute, spoke to how the field and its related organizations might address the challenge of limited provider numbers, and what other efforts are required.

Women with perimenstrual migraine attacks may also be at increased risk of medication overuse.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending September 18, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 17, 2021.

Deena Kuruvilla, MD, director, Westport Headache Institute, offered her insight into the trends in the clinical care of migraine and the effect that the pandemic has had on patients.

The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.

The division chief of vascular neurology at the University of Utah discussed the misperceptions surrounding the field of neurology, as well as the importance of increasing fellowship training.